Mr. Jerry Lai reports

PANGENOMIC HEALTH ANNOUNCES WITHDRAWAL FROM AQSE

Pangenomic Health Inc. is planning to withdraw the company's Class A common shares from the Aquis Stock Exchange Growth Market (AQSE).

Pursuant to the AQSE access rulebook, the company is required to give 20 business days of notice of its intention to withdraw from trading on AQSE. Therefore, trading in the shares will cease at 4:30 p.m., United Kingdom time, on March 15, 2024.

The shares will continue to trade on the Canadian Securities Exchange under the symbol NARA and the Frankfurt, Berlin, Hamburg, Stuttgart and Munich Stock Exchanges under the symbol LL30.

The directors of the company have taken this decision in light of the limited trading of the shares on the access market segment of the AQSE since the company's admission to the AQSE.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of U.K. domestic law by virtue of the European Union (Withdrawal) Act 2018 (MAR), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

The directors of Pangenomic health take responsibility for this announcement.

About Pangenomic Health Inc.

Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company's initial focus is to support mental health.

We seek Safe Harbor.